Industry Supported Symposia 

Please Scroll Down

Industry Supported Symposia

The following industry-supported seminars are organized by sponsors of ISLB 2022 and will be available during the 2022 Live Days.

ISS01

Time: 8:00 – 8:45
Room: Pan Am Ballroom

Title: CELLSEARCH® Circulating Multiple Myeloma Assay: A New Non-Invasive Liquid Biopsy Biomarker

Description
Description: Menarini Silicon Biosystems explains the new CELLSEARCH® Circulating Multiple Myeloma Cell (CMMC) Enumeration assay, the first-of-its-kind LDT, which directly measures levels of CD38+/CD138+/CD19-/CD45- plasma cells in one tube of peripheral blood. The CELLSEARCH® CMMC enumeration test provides new, complementary information to that of the bone marrow biopsy and other standard-of-care measures. Due to its minimally invasive nature, the test serially monitors plasma cell burden over time without requiring repeated bone marrow biopsies, with data shown to correlate plasma cell genotypes. The new CellRescue™ tube provides 120 hours of stability at room temperature making sending samples to our CLIA certified lab in Pennsylvania easy.

Presenters:

  • Cameron Lilly, PhD, Scientific Affairs Liaison
  • Frank Kuhr, PhD, Vice President of Medical Affairs

ISS02 

Time: 12:10 – 13:10
Room: Pan Am Ballroom

Title: Implementing a Patient First Approach to Clinical Decision Making with Liquid and Tissue Biopsy

Description
Description:
Liquid biopsy is a pragmatic and accessible technology for comprehensive genomic profiling and clinical decision making. This symposium will use patient cases to prompt discussion on the use of liquid biopsy in a “patient first” manner.

Topics Include:

  • The detection of challenging alterations, including fusions, using a DNA-based liquid biopsy approach
  • The complementary role of liquid and tissue biopsy
  • How liquid biopsy performance compares to tissue, what to do with a negative liquid biopsy and the growing utility of tumor fraction
  • Future monitoring approaches, including for immunotherapy

Speakers:

  • Bruna Pellini, MD – Assistant Member and Thoracic Oncologist at H. Lee Moffitt Cancer Center
  • Umberto Malapelle, PhD – Chief Supervisor Predictive Molecular Pathology Laboratory at University Federico II
  • Geoff Oxnard, MD – Vice President, Clinical Development, Foundation Medicine

ISS03

Time: 18:15 – 19:00
Room: Pan Am Ballroom

Title: Novel Applications of Liquid biopsies in Biliopancreatic Cancer and NSCLC

Description
Agenda:

Part 1 – (20 min)

  • Speaker: Matías A. Ávila, Professor of Biochemistry at the University of Navarra School of Medicine, and Director of the Hepatology Program of the Center for Applied Medical Research (CIMA)
  • Section Title: Next-generation sequencing of bile cell-free DNA for the early detection of patients with malignant biliary strictures

    • Description: Differentiation between benign and malignant (biliopancreatic tumors) biliary strictures remains challenging. We performed prospective NGS mutational analysis (OncomineTM Pan-Cancer Cell-Free Assay) of cell-free DNA (cfDNA) from bile collected during first Endoscopic retrograde cholangiopancreatography (ERCP) from patients with biliary strictures (n=68). Conventional clinico-pathological diagnosis at the time of ERCP had a ~60% sensitivity for malignancy while bile cfDNA NGS analysis had a 100% sensitivity.

Part 2 – (20 min)

  • Speaker: Leona Hamrick DHSc, PA-C, MSL-BC, Vice President of Clinical Development and Medical Affairs at Biodesix
  • Section Title: Clinical application of 72-hour blood-based next generation sequencing in patients with newly diagnosed non-small cell lung cancer
  • Description: Lung cancer is the deadliest of all cancers, but continued advancements in targeted therapies are improving patient outcomes. Without readily available genomic tumor profiling to determine eligibility for first-line targeted therapies, clinicians are faced with a dilemma to delay treatment initiation or select a treatment that may not be optimal. In the second segment of this presentation, our speaker will discuss the role of liquid biopsy in optimizing treatment decisions and the GeneStrat NGS™ genomic test, a 52-gene test that utilizes an amplicon-based next generation sequencing technology with results available within 72-hours of receipt of a blood sample.
  • Questions – Questions & Answers (5 min)

ISS04

Time: 8:00 – 8:45
Room: Pan Am Ballroom

Title: A New Era: ctDNA to guide management of solid Tumors

Description
Description: ctDNA analysis for residual disease assessment has evolved as a powerful adjunct tool to help clarify the clinical pathway when managing patients with solid tumors. Which patients should get adjuvant treatment? Is there a more reliable tool to monitor my at-risk patients? Join us as we take a closer look at the expanding data and what this could mean to help answer common clinical questions and optimize patient management.

Presenter: Adham Jurdi, MD- Medical Oncologist, GI Malignacies, Medical Director, Oncology, Natera.

ISS05

Time: 10:15 – 10:45
Room: Pan Am Ballroom 

Title: Addressing Current and Future Challenges with PD-L1 IHC Assays Utilized to help Guide NSCLC Treatment

Description
Description: Multiple PD-L1 immunohistorchemistery (IHC) assays have been developed for various checkpoint inhibitors targeting the programmed cell death-1 (PD-1/PD-L1) axis but lack of harmonization has created complexity for clinicans in interpretation of clinical trial data.
This is a first-of-its kind bridging study in advanced non-small cell lung cancer (NSCLC) demonstrating concordance of two PD-L1 IHC assays using samples from patients treated with first-line cemiplimab in EMPOWER-Lung 1

Presenter: Jean-Francois Pouliot

ISS06

Time: 12:30 – 13:30
Room: Pan Am Ballroom

Title: Clinical Applications of Liquid Biopsy

Description
Description: Presentation on clinical uses of liquid biopsy in lung, breast and colorectal cancer. Presentation and structured Q&A moderated by Dr Gandara.

Agenda:

  • 10 min intro Dr. Gandara
  • 10 min on MRD w/ CRC focus (Dr. Azzi)
  • 10 min on ID of targetable alterations and resistance w/ focus on NSCLC (Dr. Gandara?)
  • 10 min on response to therapy w/ focus on breast cancer (Dr. Sandoval)
  • 30 min structure Q&A

Presenters:

  • Ana Sandoval Leon, M.D., is a medical oncologist specializing in the treatment of breast cancer. After graduating summa cum laude from International University of Ecuador she completed her Internal Medicine residency and Hematology Oncology fellowship at Jackson Memorial Hospital/ University of Miami. During her last year of fellowship she was a Chief fellow and participated in the AACR/ASCO methods of Clinical Cancer Research Workshop in Vail. She then spend an additional year in a Breast Oncology Fellowship at University of Miami. She joined the Miami Cancer Institute in 2018. She cares for patients diagnosed with all types and stages of breast cancer. She also has expertise in breast cancer prevention and sees patients who are at high risk of developing breast cancer. Dr. Sandoval Leon is a principal investigator of multiple clinical trials. She has published articles in peer-reviewed medical journals and presented at scientific conferences. She is also a Clinical Assistant Professor at the Florida International University, Herbert Wertheim College of Medicine (FIU-HWCOM).
  • Dr. Georges Azzi is the director of Precision Medicine at the Cancer Center at Holy Cross Health in Fort Lauderdale, FL. Dr. Azzi was born and raised in Lebanon. He received his medical degree from the prestigious St. Joseph’s University Medical School. He completed his Internal Medicine residency at Northwell Health/ SIUH and fellowship in Hematology/Oncology at The University of Miami. Dr. Azzi has contributed multiple peer-reviewed articles in the field of Hematology/Oncology. Dr. Azzi has been an early adopter of cfDNA use in the clinical care of cancer patients. He has participated in clinical trials evaluating liquid biopsies and collaborated on multiple publications in this space. Dr. Azzi is board certified in Internal Medicine, Hematology and Oncology. He is fluent in English, Arabic and French and Spanish.

ISLB

About

Membership

Ways to Give

Policy

ACTIVITIES

Publications

Official Journal

CONTACTS

Dr. Oloriz, 16 Street
CP 18012 Granada - Spain

welcome@islb.info

+43 1 3950 6191
(when asked for extension please enter: 303)

Privacy policy

Legal

© 2022 - ISLB | designed & powered by publics iCC